That's the message from today's announcement that Pfizer Inc. (NYSE:PFE) is out-licensing its diabetes drug candidate ertugliflozin to Merck & Co., Inc. (NYSE:MRK).
Keep Reading →
April 29 - News
As I noted eight weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 29 - News
LONDON -- Pharmaceutical group AstraZeneca plc (ADR) (NYSE:AZN) was in the headlines at the weekend after the Telegraph anonymously quoted a top-five shareholder speaking out...
Keep Reading →
April 23 - News
Bristol Myers Squibb Co. (NYSE:BMY) has been in the spotlight for its so-called “desired” acquisitions and its size issues, along with patent expiration news.
Keep Reading →
April 19 - News
LONDON -- It's little more than a month since the FTSE 100 set a new five-year record of 6,534 points on March 12.
Keep Reading →
April 19 - News
The drug produced a statistically significant improvement in three different rating scales for depression compared to placebo.
Keep Reading →
April 17 - News
LONDON -- After offering my pick of our telecom companies last week, today I'm turning my attention to the FTSE 100 Pharmaceuticals and Biotechnology sector.
Keep Reading →
April 12 - News
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown.
Keep Reading →
April 9 - News
With the passing of the Patient Protection and Affordable Care Act in 2010, also known in shorthand as Obamacare, lawmakers and President Obama ushered in the winds of change ...
Keep Reading →
April 8 - News
April showers might bring May flowers, but the first week of the new month has already seen several health-care stocks hit full bloom.
Keep Reading →
April 7 - News
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Keep Reading →
April 7 - News
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
April 7 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
April 5 - News
LONDON -- The FTSE 100 (INDEXFTSE:UKX) has slumped 1.2% to 6,269 points as of 8 a.m. EDT. The big fear last night was for weak U.S.
Keep Reading →
April 5 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
April 3 - News
LONDON -- I have recently been evaluating the investment cases for a multitude of FTSE 100 companies.
Keep Reading →
April 2 - News
LONDON -- If you're interested in building a profitable, diversified portfolio, then you will often need to compare similar companies when choosing which share to buy next.
Keep Reading →
March 31 - News
Recently, with the loss of patents causing generic competition, the main attraction to pharmaceutical companies has been their dividend.
Keep Reading →
March 29 - News
It's been quite a while since we had a big wedding in the pharma world.
Keep Reading →
March 28 - News
LONDON -- It's easy to look back on the past month and pick the biggest risers.
Keep Reading →
March 28 - News
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 27 - News
There has been a significant rally in the share price of Celldex Therapeutics, Inc. (NASDAQ:CLDX) recently.
Keep Reading →
March 27 - News
LONDON -- Two scientists in white lab coats stare into a microscope.
Keep Reading →
March 26 - News
Every year, it appears that flu season starts earlier and earlier, and somehow, every year, the virus mutates into its "most virulent form ever." Sometimes it's a wonder we even...
Keep Reading →
March 25 - News
Normally, our weekly look at what's going on within the health-care sectors involves a mixture of health-care conferences, FDA panel meetings and decisions, and a plethora of ...
Keep Reading →
March 24 - News
The EU's decision to seize the bank accounts of ordinary Cypriot depositors was front and center again as concerns that the financial sector could come under tremendous pressure...
Keep Reading →
March 22 - News
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is bringing its kids home.
Keep Reading →
March 22 - News
It’s almost here! Johnson & Johnson (NYSE:JNJ) is eagerly awaiting a decision on its type 2 diabetes drug Invokana (canagliflozin) by the end of the month.
Keep Reading →
March 22 - News
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Keep Reading →
March 18 - News
LONDON -- There are things to love and loathe about most companies.
Keep Reading →
March 18 - News
Global pharmaceutical giants AstraZeneca plc (ADR) (NYSE:AZN), Bristol Myers Squibb Co. (NYSE:BMY), and Eli Lilly & Co. (NYSE:LLY) meet most of the growth and profitability...
Keep Reading →
March 17 - Hedge Funds
LONDON -- You have only a few weeks to use your ISA allowance before the April 5 deadline, so don't fluff this great tax-saving opportunity.
Keep Reading →
March 15 - News
With interest rates still sitting near record lows, investors looking for current income have been forced to move from fixed-income positions and into stocks to find yield.
Keep Reading →
March 15 - News
'Cliffs Natural Resources the biggest U.S.
Keep Reading →
March 13 - News
The Motley Fool recently published its list of The 25 Best Companies in America and while Bristol-Myers Squibb Co.
Keep Reading →
March 12 - News
Investing in the health care sector isn't easy.
Keep Reading →
March 7 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
March 7 - News
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market-leading therapeutic...
Keep Reading →
March 7 - News
Eight months ago, Bayer and Johnson & Johnson (NYSE:JNJ) announced that the Food and Drug Administration had issued a complete response letter for their anticoagulant, Xarelto...
Keep Reading →
March 6 - News
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech that recently launched...
Keep Reading →
March 6 - News
It looks likely to get worse before it gets better, with fears of a triple-dip recession, the loss of the AAA rating, fudged coalition politics, Mervyn King voting for more QE...
Keep Reading →
March 6 - News
Do good things come in small packages for big pharma? Most of investors' attention is given to blockbuster drugs and drugs that have the potential to be blockbusters.
Keep Reading →
March 5 - News
If you don't religiously follow the markets and are just seeing the weekly results for the first time, it would appear that this past week was simply a slight winner and nothing...
Keep Reading →
March 4 - News
Mirror, mirror, on the wall, who's the frailest big pharma of all? The patent cliff has certainly taken its toll over the past couple of years, weakening several successful pharmaceutical...
Keep Reading →
March 1 - News
I think I have uncovered the real reason why Abbott Laboratories (NYSE:ABT) decided to spin off its pharmaceutical division into AbbVie Inc (NYSE:ABBV).
Keep Reading →
February 25 - News
Shares of Novo Nordisk A/S (NYSE:NVO) are trying to recover from a recent sell-off that occurred after the FDA rejected its new drug Tresiba -- citing lack of a pre-approval ...
Keep Reading →
February 25 - News
The hits keep coming at AstraZeneca plc (ADR) (NYSE:AZN).
Keep Reading →
February 25 - News
A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a great way to gain a detailed and thorough perspective on a company and its...
Keep Reading →
February 23 - News
Irritable bowel syndrome has no organic cause and treating it usually depends on reducing symptoms of chronic abdominal pain, bloating, and gastric discomfort.
Keep Reading →
February 22 - News
Sanofi SA (ADR) (NYSE:SNY) announced this week that the Food and Drug Administration began to review the company's once-daily type 2 diabetes injectable lixisenatide.
Keep Reading →
February 21 - News
